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Biological pacemakerA group of approximately 10,000 cells in the sinoatrial node (SAN),
which is located at the entry of the right superior caval vein into the
right atrium, is responsible for regular heart beating under different
physiological conditions [1]. While the SAN is reliably working for
most of our life, in the elderly, sick sinus syndrome (SSS), or sinus
node dysfunction (SND) is prevalent [2] and responsible for 30 to 50%
of all electronic pacemaker implantations [3]. Moreover, SSS is also
often associatedwith the development of atrialﬁbrillation [4]. A fraction
of the SSS cases is familial and has a genetic basis.Moreover, several null
mutants in mice display bradyarrhythmias during postnatal life and
may serve as animal models of SSS. SSS is also the result of intrinsic
and extrinsic factors causing ﬁbrosis and other structural impairments
[4]. Treatment options are currently limited to the implantation of an
electronic pacemaker. While being effective, the electronic pacemaker
is insensitive to hormonal stimulation, has the hazards of infections,
and possibly the replacement of the pacemaker may be required.
Thus, there is demand to develop a biological pacemaker, which may
overcome these problems.
The SAN makes up an extensive area of the intercaval myocardium.
Transitory cells are surrounding the primary nodal cells, which display
both pacemaking abilities and fast conduction [5]. The SAN is densely
innervated by the autonomic nervous system. It is separated from the
workingmyocardium by connective tissue, which functions as electrical
insulation and may protect the SAN from getting hyperpolarized. Opti-
cal mapping revealed the presence of exit pathways in the human
SAN via which impulses are propagated into surrounding atrial muscle
[6]. SAN myocytes are poorly coupled due to the presence of small
amounts of slow conducting gap junctions consisting of connexin (Cx)
45 and Cx30.2 [7]. There are signiﬁcant morphological differences be-
tween SAN myocytes and chamber myocytes (Fig. 1A). Sinus node
cells have a small cell body and long thin cellular extensions [8]. The
myoﬁbrillar content in SAN myocytes is low, they lack T-tubules, but
contain larger amounts of caveolae in comparison to atrial myocytes
[9,10].
The ability of the SAN cells to act as the pacemaker of the heart de-
pends on two oscillatory mechanisms, the Ca2+-clock and the mem-
brane clock that are interlinked by the release of calcium from the
sarcoplasmatic reticulum and drive a slow depolarizing sodium currenthttp://dx.doi.org/10.1016/j.yjmcc.2016.06.006
0022-2828/© 2016 Elsevier Ltd. This is an open access article under the CC BY license (http://cvia the exchange of calcium by the sodium calcium exchanger (NCX)
[11]. The Ca2+-clock components include the ryanodine receptor
(Ryr2), the SR Ca2+-ATPase (SERCA II) and the Ca2+-storage proteins
of the sarcoplasmatic reticulum. The membrane clock components of
SAN cells include, apart from NCX, voltage-gated calcium channels (T-
and L-type) and the hyperpolarization-activated cyclic nucleotide-
gated channels (HCN1, HCN2 and HCN4) [12]. Importantly, the sodium
channel SCN5A is not expressed in the SAN, while brain-type sodium
channels are present [13]. Therefore, the upstroke velocity of the action
potential of SAN cells is signiﬁcantly smaller and the action potential has
a lower amplitude than in chamber myocytes (Fig. 1B). The ability of
SAN cells to start depolarization at hyperpolarization is due to the
funny current (If), which is speciﬁc to nodal cells and driven by HCN
channels [14]. The pacemaking ability of the SAN is therefore due to a
complex anatomy, a speciﬁc histology and myocyte morphology and
is based on a unique set of ion channels interlinked in a complex
manner.
In the early embryo, the linear heart tube consists of primitive
myocytes which all display automacity. The newly recruited cardiac
myocytes at the venous pole are acting as dominant pacemaker [15].
During heart looping, regions at the outer curvature of the heart tube
start to proliferate and acquire a chamber-speciﬁc gene expression pro-
gram, which includes high conductance type connexins (Cx40 and
Cx43) and the sodium channel SCN5A [16]. The chamber-speciﬁc gene
expression program is actively repressed in the myocytes of the sinus
venosus (SV) through a complex set of transcriptional repressors (Fig.
1C). In avian embryos, shortly after gastrulation, SAN cells have their or-
igin in the right lateral plate mesoderm just posterior of the heart ﬁeld
[17]. It is unknownwhen SAN cells become speciﬁed inmammalian em-
bryos. The sinus venosus myocardium, which makes up a large part of
the SAN starts to differentiate from embryonic day (E) 9.5 in the
mouse [18] and the SAN canmorphologically be identiﬁed from embry-
onic day (E) 11.5 [19].
Inmice, the entire early heart tube expresses the transcription factor
Nkx2.5. However, the newly added SVmyocardium at the venous pole is
derived from a lineage, which expresses Tbx18 and lacks Nkx2.5. Mice
that lack Tbx18 fail to develop the SAN head and display a malformed
SV. Despite this, the pacemaking is not affected in the null mutant,reativecommons.org/licenses/by/4.0/).
Fig. 1. Comparison of sinotrial pacemaker cells and chambermyocytes. (A)Morphological
comparison of a SAN myocyte (phase contrast) and a ventricular myocyte, which was
immunochemically stained for Ryr2 expression. Bar represents 25 μm. (B) Comparison
of the action potentials of a SAN myocyte (left) and a ventricular myocyte (right). (C)
Transcriptional network, which determines SAN development. Panel C was adapted
from [15].
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formation but dispensable for its functional development [20].
Tbx3 is also expressed in the SAN [21] and represses the transcrip-
tional program of chamber myocardium. In mice lacking Tbx3, the SAN
acquires a gene expression program normally found in the atrium
[21]. Forced expression of Tbx3 in fetal atria causes repression of cham-
ber-speciﬁc genes, upregulation of SAN-speciﬁc genes and display ec-
topic automacity [21]. Expression of Tbx3 in adult atria suppressed the
working myocardium gene program, without ectopic expression of
SAN genes [22]. Forced expression in embryonic stem (ES) cells effec-
tively induced myocytes with functional pacemaker-like abilities and
morphological features of SAN cells [23]. These data suggest that the
ability to transform working myocardium into pacemaker tissue by
Tbx3 is gradually lost during cardiac maturation.
The short stature homeobox transcription factor 2 (Shox2), another
repressor of the chamber gene expression program, acts via repression
of Nx2.5 while activating expression of the transcription factor islet 1
(Isl1). Loss of Shox2 causes hypoblastic SAN development [24]. Forced
expression in cultured ES cells induces a pacemaker-like phenotype
[25]. The transcription factor Isl1 acts downstream of Shox2 [26].
While Isl1 is only transiently expressed in cardiac mesodermal progen-
itors and lost after differentiation, it is maintained in SAN myocytes in
both the embryonic and adult heart [27]. Isl1 is required for the prolifer-
ation of SAN precursors. SAN-speciﬁc ablation of Isl1 causes embryoniclethality [28] and is accompanied by a loss of expression of Tbx3,
Shox2, aswell as ion channels important for cardiac pacemaking. Forced
expression of Isl1 in ES cells is able to upregulate SAN-speciﬁc genes and
to suppress chamber-speciﬁc genes [29].
The SAN develops only on the right side of the embryo. This
unilaterality of SAN development is achieved through direct repression
of Shox2 by Pitx2 and by the upregulation of two microRNAs, which are
able to suppress SAN genes such as Tbx3 and Shox2 [30]. In Pitx2-deﬁ-
cient embryos, SAN development occurs bilaterally [31].
In order to identify the most potent transcription factor with the
ability to convert workingmyocytes into SAN cells, a panel of transcrip-
tion factors (Shox2, Tbx3, Tbx5 and Tbx18, Tbx20) has been virally
expressed in neonatal ventricular myocytes [32]. Only Tbx18 caused
an increase in the spontaneous beating rate. Moreover, Hcn4 was in-
duced, the action potential displayed SAN-like properties and the cells
displayed SAN-like cell morphology. Tbx18 was also able to suppress
Cx43 expression [33]. Gene transfer of Tbx18 was also attempted with
adult pig hearts having a complete heart block [34]. Surprisingly, cardiac
automacity and independence of an implanted electronic pacemaker
was observed. Cells in the vicinity of the injection site displayed upreg-
ulation of Hcn4 and a downregulation of chamber-speciﬁc marker
genes. Moreover, the Tbx18-expressing cells displayed altered cell mor-
phology. This study represents the ﬁrst successful induction of a biolog-
ical pacemaker by viral gene delivery.
In a recent elegant study from the Kispert group [35], the ability of
Tbx18 to convert workingmyocardium into pacemaker cells was further
studied. The authors utilized a conditional Cre/loxP-based transgenic
approach to express Tbx18 in atrial and ventricular chamber myocardi-
um. In Myh6-Cre/Tbx18 hearts expression of the transgene was detect-
able at E12.5 and expression became more robust at the fetal stage.
Ectopic expression of Tbx18 caused right ventricular hypoplasia, atrial
dilatation and ventricular septal defects. However, no ectopic expres-
sion of SAN-speciﬁc genes was observed in the transgenic atria or ven-
tricles. Several chamber-speciﬁc genes (including Gj5, Scn5A, Kcnj2
and Kcnj3) were suppressed after Tbx18 expression. A transcriptome
analysis revealed an ectopic expression of Nppa in the ventricles and
of ventricularmarker genes (Mlc2v,Myh7, andMyl2) in the atria. Signif-
icantly, Pitx2, which is normally expressed in the left atrium was sup-
pressed. Another Cre-driver, Tagln-Cre was also utilized to further
validate these results. However, also in this case no ectopic expression
of SAN-speciﬁc genes was observed, but again aberrant cardiac mor-
phology and altered expression of chamber-speciﬁc genes were
present.
These data are in line with the results of the Tbx18 null mutant,
whichdisplayed structural abnormalities,without affectingpacemaking
[20]. However, these results do not fully agree with the recent ﬁnding
that Tbx18 is able to induce a SAN gene program when virally
overexpressed [32]. Both studies found that Tbx18 is able to suppress
chamber-speciﬁc gene expression.
An explanation for the different outcomes of the two studies might
be the use of two different animal models. These two species might dif-
ferentially utilize Tbx3 and Tbx18. It is theoretically possible that SAN-
speciﬁc gene expression is under the control of Tbx18 in the porcine
heart, while it is controlled by Tbx3 in the mouse. Another difference
lies in the experimental design: a transgenic approach was used by
Greulich et al. [35] and Tbx18 was expressed in the fetal heart, while
viral infection of the adult porcine heart was utilized in the other
study [34]. Thus, the levels of transgene expression are probably differ-
ent and most importantly the developmental time at which Tbx18 was
expressed differed in the two studies.
Nonetheless, the presence of atrial and ventricular pathologies and
the loss of expression of vital genes, such as Pitx2, after ectopic expres-
sion of Tbx18 in the mouse heart should be taken seriously. Therefore,
further research is required to rule out any serious side effects, which
might accompany the induction of a SAN gene program in the chamber
myocardium.
265EditorialIn conclusion, morework is required, in particular in the porcine and
human heart, to establishwhether there are species-speciﬁc differences
in the transcriptional control of SAN speciﬁcation. While the results of
the viral overexpression of Tbx18 are exciting and highly encouraging
towards the goal of developing a biological pacemaker, there is now ev-
idence that theremight be the risk of cardiac pathologies as the result of
ectopic Tbx18 expression.
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